. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2019 Oct 12;8(3):953–964. doi: 10.1016/j.jaip.2019.09.033

Table 4.

Association between albuterol dose response and outcome occurrence by 12 months.

	Adjusted odds ratio (95% confidence interval)
	Exacerbation	ED visit	Hospitalization
Model 1¹
540 mcg vs. 360 mcg	1.28 (0.87, 1.88)	1.13 (0.74, 1.73)	2.28 (1.07, 4.85)^*
720 mcg vs. 360 mcg	2.65 (1.36, 5.17)^*	2.70 (1.35, 5.38)^*	4.93 (1.82, 13.41)^*
Model 2²
540 mcg vs. 360 mcg	1.29 (0.87, 1.90)	1.13 (0.73, 1.74)	2.57 (1.20, 5.52)^*
720 mcg vs. 360 mcg	2.59 (1.32, 5.08)^*	2.59 (1.29, 5.20)^*	4.78 (1.73, 13.21)^*
Model 3³
540 mcg vs. 360 mcg	1.15 (0.77, 1.71)	0.97 (0.62, 1.52)	2.26 (1.04, 4.90)^*
720 mcg vs. 360 mcg	2.19 (1.10, 4.34)^*	2.12 (1.03, 4.32)^*	3.87 (1.39, 10.80)^*
Model 4⁴
540 mcg vs. 360 mcg	1.07 (0.71, 1.60)	0.93 (0.59, 1.45)	1.98 (0.91, 4.34)
720 mcg vs. 360 mcg	2.10 (1.05, 4.20)^*	2.05 (1.01, 4.20)^*	3.55 (1.25, 10.10)^*

p < 0.05

Adjusted for age group

Adjusted for age group and demographic features (sex, race, ethnicity)

Adjusted for age group, demographic features and ICS use

⁴

Adjusted for age group, demographic features, ICS use, and baseline airflow obstruction